Oxigen Services

Oncotelic Reports Q3 2022 Compared to Q3 2021 Financial Results

Retrieved on: 
Monday, November 21, 2022
HSDD, Female, Cocaine, ED, Sertraline, Communication, PPP, Apomorphine, Food, Cancer, Hartmut Geerken, G&A, Mohammad Ali Allahdadi, Safety, Therapy, Melanoma, Orthostatic syncope, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, CA4P, Optimism, Oxigen Services, Parkinson's disease, Disease, Fluoxetine, McMahon, Annual report, BARDA, Diffuse intrinsic pontine glioma, Male, Hypotension, PD, Research, Risk, BMJ, Ageing, PDE5, KJ, Circulatory system, Clinical trial, JV, Survival, Erectile dysfunction, Form 10-K, Woman, FSD, Manifest and latent functions and dysfunctions, Pharmaceutical industry, Bremelanotide

In comparing the Companys operating results for the three months ended September 30, 2022, and 2021, respectively, our net loss reduced by approximately $1.0 million.

Key Points: 
  • In comparing the Companys operating results for the three months ended September 30, 2022, and 2021, respectively, our net loss reduced by approximately $1.0 million.
  • Further, our general and administrative expenses decreased by approximately $0.6 million primarily due to reduced compensation expense of approximately $0.6 million.
  • We expect our R&D and G&A expense to remain steady or reduce for the remainder of the year 2022.
  • Oncotelic acquired AL-101, during the 4th quarter of 2021, for the intranasal delivery of apomorphine.

ONCOTELIC REPORTS Q2 2022 COMPARED TO Q2 2021 FINANCIAL RESULTS

Retrieved on: 
Monday, August 22, 2022
BMJ, Cancer, Sexual dysfunction, DIPG, Survival, Research, Ageing, Safety, Form 10-K, PDE5, Apomorphine, McMahon, Regulation of tobacco by the U.S. Food and Drug Administration, Therapy, Oxigen Services, FSD, Disease, Man, AML, Risk, ED, Optimism, Food, Male, KJ, Mohammad Ali Allahdadi, SEC, Hartmut Geerken, JV, HSDD, PD, Company, Manifest and latent functions and dysfunctions, Female, Communication, Circulatory system, G&A, Orthostatic syncope, Sertraline, Fluoxetine, Hypotension, Annual report, Woman, CA4P, Melanoma, Private Securities Litigation Reform Act, Cocaine, Forward-looking statement, Patient, New, Animal, Mobile phone, Pharmaceutical industry, Bremelanotide

Comparing Q2 2022 to Q2 2021, we reported a net profit, before non-controlling interests, of approximately $16.0 million compared to a net loss of approximately $3.6 million, respectively.

Key Points: 
  • Comparing Q2 2022 to Q2 2021, we reported a net profit, before non-controlling interests, of approximately $16.0 million compared to a net loss of approximately $3.6 million, respectively.
  • Comparing our research and development (R&D) expenses between Q2 2022 and Q2 2021, our R&D expenses decreased by approximately $0.8 million for Q2 2022 compared to the Q2 2021, primarily due to personnel and operational expenses related to OT-101 being borne by the JV.
  • Comparing our general and administrative (G&A) expenses between Q2, 2022 and Q2 2021, our G&A expenses decreased by approximately $2.6 million, primarily due to lower stock compensation expense of approximately $2.0 million during Q2 2021 as compared to $25 thousand during Q2 2022, and lower compensation and operational expenses of approximately $0.3 million which was borne by the JV.
  • Comparing our interest expense for Q2 2022 and Q2 2021, our interest expense increased by $0.7 million based on approximately $1.1 million for Q2 2022, primarily in connection with debt raised from convertible notes and the JH Darbie Financing, the November 2021 to March 2022 Financing and May/June 2022 financing as compared to $0.4 million for Q2 2021, in connection with debt raised from convertible notes and JH Darbie during 2021.

Renovacor Announces the Appointment of Fred Driscoll as Chief Financial Officer

Retrieved on: 
Monday, March 28, 2022
Biotechnology, Genetics, Health, Cardiology, Company, DCM, Instrumentation Laboratory, Sale, RCOR, Government, Forward-looking statement, NYSE, Securities & Exchange Commission of Pakistan, IND, CFO, Lists of diseases, CEO, Bentley University, Senior, Private Securities Litigation Reform Act, Quality of life, U.S. Securities and Exchange Commission, GlaxoSmithKline, Biology, BAG3, Time, COVID-19, Intellectual property, Microsoft Dynamics 365 for Finance and Operations, Accounting, Heart failure, Patient, Disease, Oxigen Services, Pharmaceutical industry, Management, Anatomical terms of motion, Finance, GeneLab

Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced the appointment of Fred Driscoll as Chief Financial Officer (CFO).

Key Points: 
  • Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced the appointment of Fred Driscoll as Chief Financial Officer (CFO).
  • Fred has a wealth of experience guiding financial strategy for publicly-traded biotech companies and we are thrilled to welcome him to Renovacor, said Magdalene Cook, M.D., Chief Executive Officer of Renovacor.
  • Mr. Driscoll added, Renovacors impressive management team, strong financial foundation, and sound scientific strategy make the opportunity to serve as its CFO a truly exciting one.
  • Mr. Driscoll joins Renovacor with over 25 years of executive experience in the biotech industry.

Oncotelic Presenting at BiotechGate Digital Partnering

Retrieved on: 
Wednesday, January 19, 2022
Survival, Forward-looking statement, Melanoma, Lung, Patient, Virology, Annual report, Glioma, Private Securities Litigation Reform Act, SEC, Form 10-K, RNA, COVID-19, Severe acute respiratory syndrome coronavirus 2, CA4P, Safety, Adult, Optimism, CEO, Cocaine, GLOBE, AML, Glioblastoma, Pancreatic cancer, New, Cancer, Intelligence, Oxigen Services, Therapy, Company, AI, Food, Communication, FDA, Food and Drug Administration Amendments Act of 2007, DIPG, Risk, Pharmaceutical industry, TGF

AGOURA HILLS, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (Oncotelic or the Company) (OTCQB:OTLC), a leading developer of TGF- therapeutics for oncology and virology, today announced that Dr. Vuong Trieu, Oncotelic Chairman and CEO, will be presenting the Company immunotherapy pipeline at BiotechGate Digital Partnering Feb 7 - 11, 2022.

Key Points: 
  • AGOURA HILLS, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (Oncotelic or the Company) (OTCQB:OTLC), a leading developer of TGF- therapeutics for oncology and virology, today announced that Dr. Vuong Trieu, Oncotelic Chairman and CEO, will be presenting the Company immunotherapy pipeline at BiotechGate Digital Partnering Feb 7 - 11, 2022.
  • Biotechgate Digital Partnering is a premier platform for business licensing and collaboration focusing on companies developing drugs, diagnostics and medical devices.
  • It is an ideal platform to unveil the fully integrated platform of immunotherapies at Oncotelic.
  • OT-101, the lead immuno-oncology drug candidate of Oncotelic, is a first-in-class anti-TGF- RNA therapeutic that exhibited single agent activity in relapsed/refractory cancer patients.

Oncotelic Initiates Phase 1 Trial Evaluating CA4P in Combination with Pembrolizumab for Melanoma

Retrieved on: 
Wednesday, January 5, 2022
Therapy, Toxicity, COVID-19, Severe acute respiratory syndrome coronavirus 2, Melanoma, Pembrolizumab, Intelligence, Trial of the century, Shaper/Mechanist universe, Form 10-K, Company, Pancreatic cancer, Patient, Communication, Cancer, Forward-looking statement, US, Risk, Bevacizumab, Private Securities Litigation Reform Act, Ovarian cancer, Survival, AML, Oxigen Services, SEC, Virology, Clinical trial, FDA, DIPG, CA4P, RNA, Uveal melanoma, Glioma, GLOBE, New, Cocaine, Paclitaxel, Optimism, Annual report, Pharmaceutical industry, TGF, Safety

The Phase 1 Clinical Trial is designated as S101: Phase 1, Prospective, Multicenter, Open-Label, Single Arm Study of Safety and Initial Efficacy of CA4P in Combination with anti-PD1 (pembrolizumab) in Patients with Recurrent Metastatic Cutaneous or Uveal Melanoma.

Key Points: 
  • The Phase 1 Clinical Trial is designated as S101: Phase 1, Prospective, Multicenter, Open-Label, Single Arm Study of Safety and Initial Efficacy of CA4P in Combination with anti-PD1 (pembrolizumab) in Patients with Recurrent Metastatic Cutaneous or Uveal Melanoma.
  • The Company believes that the combination of CA4P together with checkpoint inhibitors, such as pembrolizumab, could be synergistic.
  • OT-101 also has shown activity against SARS-CoV-2 and has completed a phase 2 trial against COVID-19 with data cleaning and datalock ongoing.
  • Oncotelic also has rare pediatric designation for DIPG (OT-101), melanoma (CA4P), and AML (OXi 4503).

ONCOTELIC ANNOUNCES THAT ORF8 MUTATIONS ARE DRIVING THE EVOLUTION OF THE DELTA AND THE OMICRON VARIANTS.

Retrieved on: 
Wednesday, December 22, 2021
Pancreatic cancer, Mutation, RNA, Genome, Entropy, Communication, Publication, Investigations into the origin of COVID-19, Patient, Private Securities Litigation Reform Act, Cancer, Cocaine, CEO, AML, Form 10-K, MedRxiv, Optimism, Acquisition, New, Serum, SEC, Survival, Therapy, Forward-looking statement, COVID-19, DIPG, Treatment, CA4P, Tree, Oxigen Services, Intelligence, Company, F120, Safety, Severe acute respiratory syndrome coronavirus 2, Annual report, CLIN, Risk, Melanoma, Radio spectrum, Glioma, GLOBE, Virology, Pharmaceutical industry, TGF, Omicron, Delta, Artemisinin, COVID

The analysis allows us to position our therapeutic and vaccine platform against ORF8 to address this pandemic as it further mutates.

Key Points: 
  • The analysis allows us to position our therapeutic and vaccine platform against ORF8 to address this pandemic as it further mutates.
  • ORF8 and the evolution of the Delta and Omicron variants.
  • Further mutations of these two residues are creating new lineage trees that are offshoots from the Delta backbone.
  • More importantly the further mutational expansion of the S-protein in the emerging Omicron variant is now followed with the acquisition of ORF8 mutations 119 and 120.

DGAP-News: Oncotelic's Dr. Anthony Maida to Present at 2nd Annual TGF-β for Immuno-Oncology Drug Development Summit in January 2022

Retrieved on: 
Monday, December 20, 2021
Forward-looking statement, Therapy, AbbVie, COVID, Cocaine, RNA, Melanoma, AML, Company, CA4P, Severe acute respiratory syndrome coronavirus 2, Optimism, Cancer, Intelligence, Private Securities Litigation Reform Act, Translational medicine, Industry, COVID-19, Survival, Risk, SEC, Escape Room, Annual report, Form 10-K, DIPG, CEO, Safety, Patient, New, Virology, Glioma, Oxigen Services, Pancreatic cancer, Communication, Medical device, Pharmaceutical industry, TGF, Genentech, Takeda

noted Dr. Anthony Maida, Chief Clinical Office - Translational Medicine.

Key Points: 
  • noted Dr. Anthony Maida, Chief Clinical Office - Translational Medicine.
  • TGF- has been recognized by drug developers, for many years, as holding vast therapeutic potential due to its vital role in cell functioning and signaling.
  • But its complex nature and its ability to be both tumor promoting and tumor suppressing has presented many obstacles for the industry.
  • Forward-looking statements are based on expectations and assumptions as of the date of this press release.

Oncotelic’s Dr. Anthony Maida to Present at 2nd Annual TGF-β for Immuno-Oncology Drug Development Summit in January 2022

Retrieved on: 
Tuesday, December 14, 2021
Forward-looking statement, Therapy, AbbVie, COVID, Cocaine, Melanoma, RNA, AML, Company, CA4P, Severe acute respiratory syndrome coronavirus 2, Optimism, Cancer, Intelligence, Private Securities Litigation Reform Act, Industry, COVID-19, Survival, Risk, SEC, Escape Room, Annual report, Form 10-K, DIPG, CEO, Safety, Patient, New, Virology, Glioma, GLOBE, Oxigen Services, Pancreatic cancer, CA, Communication, Medical device, Pharmaceutical industry, TGF, Genentech, Takeda

noted Dr. Anthony Maida, Chief Clinical Office Translational Medicine.

Key Points: 
  • noted Dr. Anthony Maida, Chief Clinical Office Translational Medicine.
  • TGF- has been recognized by drug developers, for many years, as holding vast therapeutic potential due to its vital role in cell functioning and signaling.
  • But its complex nature and its ability to be both tumor promoting and tumor suppressing has presented many obstacles for the industry.
  • OT-101, the lead immuno-oncology drug candidate of Oncotelic, is a first-in-class anti-TGF- RNA therapeutic that exhibited single agent activity in relapsed/refractory cancer patients.

Oncotelic Initiates Phase 2 Trial Evaluating OT-101 in Combination with KEYTRUDA® for Mesothelioma

Private Securities Litigation Reform Act, Patient, Lung, Trial of the century, Pancreatic cancer, CEO, Safety, Oxigen Services, Cancer, Cocaine, Risk, AI, Forward-looking statement, Company, AML, Tumor microenvironment, Severe acute respiratory syndrome coronavirus 2, DIPG, SEC, Therapy, COVID-19, Annual report, Glioblastoma, Cytokine, Melanoma, Escape Room, New, Virology, Survival, US, Communication, Mesothelioma, Optimism, GLOBE, Pembrolizumab, RNA, Form 10-K, PD-1, CA4P, Glioma, MPM, Intelligence, COVID, Pharmaceutical industry

M201: Phase 2 Trial of TGF- Inhibition (OT-101) with Anti-PD-1 (Pembrolizumab) in Patients with Malignant Pleural Mesothelioma (MPM) Failing to Achieve or Maintain Response to Checkpoint Inhibition.

Key Points: 
  • M201: Phase 2 Trial of TGF- Inhibition (OT-101) with Anti-PD-1 (Pembrolizumab) in Patients with Malignant Pleural Mesothelioma (MPM) Failing to Achieve or Maintain Response to Checkpoint Inhibition.
  • OT-101 is a first-in-class anti-TGF- ribonucleic acid (RNA) therapeutic that has exhibited single agent activity in relapsed/refractory cancer patients in multiple clinical trials.
  • OT-101, the lead immuno-oncology drug candidate of Oncotelic, is a first-in-class anti-TGF- RNA therapeutic that exhibited single agent activity in relapsed/refractory cancer patients.
  • OT-101 also has shown activity against SARS-CoV-2 and has completed a phase 2 trial against COVID-19 with data cleaning and datalock ongoing.

DGAP-News: ONCOTELIC ANNOUNCES POSITIVE TOPLINE DATA FOR OT-101 C001 COVID STUDY

Retrieved on: 
Tuesday, November 23, 2021
Sucre, Private Securities Litigation Reform Act, Patient, Pancreatic cancer, CEO, Safety, Oxigen Services, Cancer, Cocaine, Risk, Forward-looking statement, Company, Population, Viral load, AML, Severe acute respiratory syndrome coronavirus 2, DIPG, SEC, Therapy, Incidence, COVID-19, Vaccine, Annual report, SDTM, Cytokine release syndrome, Melanoma, Escape Room, New, Virology, Survival, Communication, Standard of care, Optimism, TGF, RNA, Mortality, Form 10-K, SOC, Area studies, Dexamethasone, Adams, CA4P, Glioma, Translational medicine, Intelligence, COVID, Pharmaceutical industry, Generic drug

Consequently, inhibiting TGF- by OT-101 is expected to impact both cancer and COVID.

Key Points: 
  • Consequently, inhibiting TGF- by OT-101 is expected to impact both cancer and COVID.
  • On October 18, Data lock and Study Data and Analysis Data Models (SDTMs & ADaMS Databases) were generated for a Phase 2 C001 Covid Study: 'A Double-Blind, Randomized, Placebo Controlled, Multi-Center Study of OT-101 in Hospitalized COVID-19 Subjects'.
  • End of treatment (Day 7) mortality for the entire study population was 4.5% OT-101 versus 20% for placebo.
  • Oncotelic also has rare pediatric designation for DIPG (OT-101), melanoma (CA4P), and AML (OXi 4503).